With Rucaparib Approval, Prostate Cancer Joins the Precision Oncology Era
The FDA’s accelerated approval of the PARP inhibitor rucaparib brings clinical prostate oncology into the precision medicine era.
Bryant Furlow
Contributing Writer
Bryant Furlow is a contract medical journalist for the Haymarket Medical Network. He holds a BS in biology (summa cum laude) from the University of New Mexico. He covers radiation oncology, immunotherapy, tumor biology, clinical research and health care policy. Prior to joining Haymarket in 2010, Bryant was a newspaper reporter in New Mexico, where he won awards for public health and investigative journalism. He also reports for The Lancet Oncology news desk.
